Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.
Full article body is being fetched in the background. Refresh in a moment to see the complete paragraphs. For now this page shows a summary and AI analysis.